Global Healthcare Opportunities, or GHO Capital, was founded in 2014 as a specialist healthcare investment adviser based in London. The firm was built from a shared experience and long-standing history of creating and backing businesses, accelerating growth, delivering value and championing success in the sector through prior roles with healthcare industry leader Quintiles, 3i Group, J.P. Morgan and TPG.
We actively evaluate companies with a European presence and global potential within the four healthcare sub-sectors of Outsourced services, PharmaBio, MedTech and Patient services. Our sourcing strategy is based upon a combination of expert healthcare sub-sector knowledge and a global network of industry relationships.
Our experienced leadership team brings a unique fusion of private equity, investment banking and industry competencies. The team is designed to provide insight and expertise in supporting company growth and maximising potential. We work alongside management teams who benefit from our proprietary insight and unfettered access to our unique global platform of experience, resource and expert networks.
For more information please visit www.ghocapital.com.
We actively evaluate companies with a European presence and global potential within the four healthcare sub-sectors of Outsourced services, PharmaBio, MedTech and Patient services. Our sourcing strategy is based upon a combination of expert healthcare sub-sector knowledge and a global network of industry relationships.
Our experienced leadership team brings a unique fusion of private equity, investment banking and industry competencies. The team is designed to provide insight and expertise in supporting company growth and maximising potential. We work alongside management teams who benefit from our proprietary insight and unfettered access to our unique global platform of experience, resource and expert networks.
For more information please visit www.ghocapital.com.
Location: United Kingdom, England, Westminster
Employees: 11-50
Founded date: 2014
Portfolio 14
| Date | Name | Website | Total Raised | Location |
| - | X-Chem | x-chemrx.com | - | United Sta... |
| - | Velocity C... | velocityclinical.com | - | United Sta... |
| - | Linimed | linimed.de | - | Germany, T... |
| - | Validant | validant.com | - | United Sta... |
| - | VISUfarma | visufarma.com | - | United Kin... |
| - | FairJourne... | fjb.pt | - | Portugal, ... |
| - | BioAgilyti... | bioagilytix.com | - | United Sta... |
| - | Quotient S... | quotientsciences.com | - | United Kin... |
| - | Alcaliber | alcaliber.com | - | - |
| - | Ardena | ardena.com | - | Belgium, E... |
Show more
News 47
| Date | Title | Description |
| 08.07.2021 | Two Labs, an Envision Pharma Group company acquires Riparian | 08 July 2021 |
| 28.06.2021 | GHO Capital announces the sale of DNA Diagnostics Center to Eurofins | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, announces the sale of DNA Diagnostics Center (“DDC”) to Eurofins, a publicly traded global laboratory te... |
| 15.04.2021 | Validant acquires Oriel STAT A MATRIX, a global consultancy and training firm for the medical device industry | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding the acquisition of Oriel STAT A M... |
| 08.04.2021 | GHO Capital acquires Velocity Clinical Research, signalling evolution of clinical trial site industry | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of Velocity Clinical Research, from NaviMed Capital (“NaviMed”) and other investors, ... |
| 07.04.2021 | Sterling Pharma Solutions acquires ADC Bio | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Sterling Pharma Solutions, regarding the acquisition of ADC... |
| 22.03.2021 | Envision Pharma Group acquires doDOC to enable seamless document collaboration as part of iEnvision, its global medical affairs platform | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Envision Pharma Group, regarding the acquisition of doDOC.... |
| 04.02.2021 | GHO appoints David W. Miller and Geoffrey Hamilton-Fairley as Operating Partners | Appointments will support GHO through deal origination and portfolio company support, bringing extensive experience in market access, MedTech and advanced therapies from industry and consulting careers. |
| 26.01.2021 | X-Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, X-Chem, regarding the acquisition of IntelliSyn and sister ... |
| 02.12.2020 | Validant acquires IDEC, a leading regulatory consultancy in Japan | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding the acquisition of IDEC. |
| 12.11.2020 | Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma | Acquisition follows increased investment in Envision from GHO Capital and its partners |
Show more
Mentions in press and media 13
| Date | Title | Description |
| 09.03.2026 | Agilent покупает американского производителя инструментов и реагентов для исследований рака Biocare за $950 млн | Компания Agilent Technologies Inc. договорилась о приобретении частной компании Biocare Medical, которая производит оборудование и материалы для исследований рака. Сделка полностью оплачивается денежными средствами и оценивается в $950 млн.... |
| 31.10.2025 | GHO Capital Secures €2.5 Billion Fund, Dominating Global Healthcare Private Equity | GHO Capital secures over €2.5 billion for its fourth fund, GHO Capital IV LP. This monumental close positions GHO as Europe's largest healthcare-focused private equity firm, with total assets under management now approximately €9 billion. T... |
| 28.10.2025 | London-based GHO Capital boosts healthcare fund size by 25% to €2.5 billion | Global Healthcare Opportunities, the UK specialist investor in global healthcare, today announces the final close of its fourth fund, GHO Capital IV LP, raising over €2.5 billion of capital available to invest. Fund IV further diversifies G... |
| 28.10.2025 | GHO Capital: Fund IV Closed At €2.5 Billion, Expanding Leadership In Global Healthcare Private Equity | Global Healthcare Opportunities (GHO Capital), a leading European specialist investor in global healthcare, announced the final close of its fourth fund, GHO Capital IV LP, with more than €2.5 billion (~$2.9 billion) in capital commitments.... |
| 29.09.2025 | Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital | LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi... |
| 25.11.2024 | GHO Capital Celebrates 10-Year Anniversary as Europe’s Leading Healthcare Private Equity Group | London, UK – 25 November 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, marks a decade of transformative impact in the healthcare investment landscape. Sir ... |
| 01.07.2024 | GHO Capital realises significant return with sale of FairJourney Biologics | GHO Capital realises significant return with sale of FairJourney Biologics Under GHO’s ownership FairJourney Biologics has become an established leader in antibody discovery and development, with more than 5x revenue growth since 2019 GHO t... |
| 26.09.2022 | Leading pharmaceutical executive Jennifer Fillman joins evidence-based solution provider Genesis Research as Chief Financial Officer | Jennifer’s experience in developing pharmaceutical business and her in-depth knowledge of the industry will be invaluable as we expand to meet the increasing demand for the agile, tech-enabled research partnerships we’ve introduced to the i... |
| 08.12.2021 | Rallyday Partners and the Founders of Genesis Research Sell to GHO Capital Partners in a Landmark Transaction | We are honored that we supported Genesis as its first outside investor and the tremendous progress we made together as partners DENVER (PRWEB) December 08, 2021 Rallyday Partners (Rallyday), a Denver-based private equity firm executing its ... |
| 20.11.2019 | GHO Capital raises €975m in largest ever European healthcare fund | London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, announces the successful final close of its second fund, GHO Capital Fund II LP (“the Fund” or “Fund II”), at its har... |